Payment overview · 2025
General Payments
$1,179.82
50 reported records · 17 companies
Healthcare provider profile · identity verified
Azhar Muttalib, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TORRANCE, CA · NPI 1124054721
Verified facts
What the public records show
CMS Open Payments records show Azhar Muttalib, M.D. received $1,179.82 in general payments during 2025 across 50 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 413 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $184.62 | 15.7% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $106.59 | 9.0% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $106.59 | 9.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $100.79 | 8.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $98.45 | 8.3% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $88.38 | 7.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.09 | 7.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.86 | 6.3% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $64.23 | 5.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $62.88 | 5.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $60.54 | 5.1% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $47.03 | 4.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.45 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.09 | 2.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.32 | 2.0% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $15.12 | 1.3% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $14.79 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,179.82 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $184.62 | 10 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $106.59 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $100.79 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $88.38 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $82.08 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $73.60 | 3 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $64.23 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $62.88 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.10 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $60.54 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $48.06 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $48.06 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $48.06 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $47.03 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.77 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.80 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.80 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 413 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 168 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 150 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
168 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
150 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
413 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 648 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 523 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 517 | 120 |
| Eliquis | Apixaban | 413 | 52 |
| Metformin Hcl | Metformin Hcl | 325 | 86 |
| Lisinopril | Lisinopril | 321 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 305 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 298 | 79 |
| Gabapentin | Gabapentin | 282 | 65 |
| Furosemide | Furosemide | 279 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 59 |
| Losartan Potassium | Losartan Potassium | 253 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 222 | 40 |
| Omeprazole | Omeprazole | 207 | 51 |
| Carvedilol | Carvedilol | 192 | 47 |
| Donepezil Hcl | Donepezil Hcl | 189 | 28 |
| Lorazepam | Lorazepam | 181 | 32 |
| Farxiga | Dapagliflozin Propanediol | 168 | 39 |
| Famotidine | Famotidine | 165 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 33 |
| Levetiracetam | Levetiracetam | 151 | 23 |
| Jardiance | Empagliflozin | 150 | 30 |
| Mirtazapine | Mirtazapine | 136 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 29 |
| Potassium Chloride | Potassium Chloride | 130 | 32 |
| Simvastatin | Simvastatin | 129 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 35 |
| Azithromycin | Azithromycin | 118 | 83 |
| Divalproex Sodium | Divalproex Sodium | 114 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 114 | 25 |
| Meclizine Hcl | Meclizine Hcl | 95 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 27 |
| Risperidone | Risperidone | 88 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 17 |
| Latanoprost | Latanoprost | 85 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 13 |
| Lactulose | Lactulose | 82 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 20 |
| Alendronate Sodium | Alendronate Sodium | 79 | 23 |
| Sertraline Hcl | Sertraline Hcl | 79 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 77 | 13 |
| Tramadol Hcl | Tramadol Hcl | 74 | 26 |
| Clonazepam | Clonazepam | 73 | suppressed |
| Memantine Hcl | Memantine Hcl | 73 | 11 |
| Temazepam | Temazepam | 73 | 18 |
| Allopurinol | Allopurinol | 70 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | suppressed |
| Spironolactone | Spironolactone | 66 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 17 |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Prednisone | Prednisone | 61 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 19 |
| Baclofen | Baclofen | 59 | 11 |
| Finasteride | Finasteride | 58 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 12 |
| Xarelto | Rivaroxaban | 57 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 15 |
| Nateglinide | Nateglinide | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 52 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 12 |
| Ozempic | Semaglutide | 51 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Cefdinir | Cefdinir | 49 | 37 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 45 | suppressed |
| Celecoxib | Celecoxib | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Alprazolam | Alprazolam | 39 | suppressed |
| Atenolol | Atenolol | 39 | 13 |
| Lacosamide | Lacosamide | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 14 |
| Linzess | Linaclotide | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 21 |
| Digoxin | Digoxin | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 12 |
| Monoject Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Fluocinonide | Fluocinonide | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Etodolac | Etodolac | 26 | 14 |
| Humulin R | Insulin Regular, Human | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | 13 |
| Valsartan | Valsartan | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 12 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | 15 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Levocarnitine | Levocarnitine | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 19 | suppressed |
| Nystatin | Nystatin | 19 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Travoprost | Travoprost | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Ertapenem | Ertapenem Sodium | 17 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Betaxolol Hcl | Betaxolol Hcl | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,179.82 · 50 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | ABRYSVO, AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, COLLAGENASE SANTYL, COMIRNATY, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, KISUNLA, LEQEMBI, LOREEV XR, LifeVest, NURTEC ODT, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, VRAYLAR, Wegovy, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error